Screener / SEC EDGAR /CIK 0001388658 /10-K filed Feb 19, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Instruments

iRhythm Holdings, Inc. IRTC

Compare with peers Embed
Earnings releases

Latest results release: Nov 5, 2026

8-K item 2.02, exhibit 99

What IRTC's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

What the company says its adjusted numbers leave out:

Adjusted EBITDA is defined as net income (loss) before income tax provision, depreciation and amortization, interest expense, and interest income and as further adjusted excludes non-cash operating charges for stock-based compensation expense, changes in fair value of strategic investments, impairment and restructuring charges, business transformation costs, certain intellectual property litigation expenses, certain corporate litigation settlements (net of expected insurance recoveries), costs related to the cybersecurity incident (net of expected insurance recoveries), and loss on extinguishment of debt. release Aug 6, 2026

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 5, 2026 · EX-99.1

iRhythm Holdings Announces Third Quarter 2026 Financial Results

Open on SEC

-- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company with a mission to create trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended September 30, 2026.

• Gross margin of 74.2%, a 310-basis point increase compared to third quarter 2025

• GAAP net loss of $29.9 million, a $24.6 million increase in net loss compared to third quarter 2025

• Adjusted EBITDA and adjusted EBITDA margin of $51.2 million and 23.1%, respectively, a $29.6 million and 1,190 - basis point improvement, respectively, compared to third quarter 2025

• Unrestricted cash, cash equivalents, and marketable securities of $560.7 million as of September 30, 2026

• Increased fiscal year 2026 revenue guidance to $890 million to $895 million and adjusted EBITDA margin guidance to 15.5% to 16.0%

• Delivered another strong quarter, driven by healthy volume-led revenue growth of Zio Monitor and robust margin expansion, with broad-based momentum across cardiology, primary care, innovative channels and international markets

• Completed the acquisition of VitalConnect on October 5, 2026, broadening our cardiac monitoring portfolio with an immediate FDA-cleared mobile cardiac telemetry offering, advancing our multi-vitals strategy, and expanding our addressable market across the continuum of care

• Published three large-scale real world studies demonstrating product superiority of Zio AT (CAMELOT-ALERT 1 ), Zio Long-Term Continuous Monitoring (EXCALIBUR 2 ), and improvements in Zio Monitor performance and diagnostic yield compared with Zio XT 3 in over 1.7 million total patients

• Submitted FDA 510(k) applications for pediatric use with our Zio Monitor long- term continuous monitoring business

• Closed a new $300 million senior secured revolving credit facility on November 3, 2026, providing additional liquidity to support our long-term growth objectives

“Our third quarter results reflect the continued strength of our core business. Demand for Zio Monitor remains robust, exceeding our expectations in the quarter, driven by volume growth across care settings and channels. We also continued to take meaningful steps forward with significant margin expansion, and consistent execution against our strategic priorities,” said Quentin Blackford, President and Chief Executive Officer of iRhythm. “With the acquisition of VitalConnect now closed, we are encouraged by the early opportunities we see to broaden our capabilities and serve more patients within the ambulatory cardiac monitoring market and across the continuum of care. With an immediate FDA-cleared mobile cardiac telemetry device, we are excited to be able to offer the marketplace a best-in-class MCT portfolio of options. We remain focused on advancing innovation, expanding access to Zio, and investing in the growth initiatives that we believe will create durable value for patients, clinicians, and stockholders.”

Revenue for the third quarter of 2026 was $221.6 million, up 14.9% from $192.9 million during the same period in 2025. The increase was driven primarily by sustained volume demand across our customer base, reflecting continued strength in our core business and contributions from newer growth channels.

Gross profit for the third quarter of 2026 was $164.5 million, up 20.0% from $137.1 million during the same period in 2025, while gross margin was 74.2%, a 310-basis point improvement compared to the third quarter of 2025. The increase in gross profit was primarily due to increased volume of Zio services, as well as a one-time benefit from tariff refunds of approximately $3.1 million. The increase in gross margin was primarily driven by continued operational efficiencies, product mix, a tariff refund one-time benefit, and disciplined execution.

Operating expenses for the third quarter of 2026 were $197.0 million, compared to $145.6 million for the same period in 2025. Adjusted operating expenses for the third quarter of 2026 were $138.6 million, compared to $141.4 million during the same period in 2025. The decrease in adjusted operating expenses, period over period, reflects a disciplined approach to investment, as we funded key growth initiatives while thoughtfully managing costs across the broader organization.

GAAP net loss for the third quarter of 2026 was $29.9 million, or net loss per diluted share of $0.90, compared with GAAP net loss of $5.2 million, or net loss per diluted share of $0.16, for the same period in 2025. Adjusted net income for the third quarter of 2026 was $27.8 million, or net income per diluted share of $0.82, compared with an adjusted net loss of $2.0 million, or net loss per diluted share of $0.06, for the same period in 2025. The improvement was primarily driven by our revenue growth and operating leverage achieved through implementation of efficiency initiatives.

Unrestricted cash, cash equivalents, and marketable securities were $560.7 million as of September 30, 2026.

For the full year 2026, iRhythm expects revenue between $890 million and $895 million, which includes approximately $16 million of expected VitalConnect revenue contribution from the October 5, 2026 acquisition close through year- end. iRhythm also expects adjusted EBITDA margin between 15.5% and 16.0%, inclusive of VitalConnect. iRhythm’s guidance reflects continued volume-led growth and operating leverage while maintaining disciplined investment in innovation and market expansion.

iRhythm’s management team will host a conference call today beginning at 1:30 p.m. PT/4:30 p.m. ET. Interested parties may access a live and archived webcast of the presentation on the “Events & Presentations” section of the company’s investor website at investors.irhythmtech.com.

iRhythm is a leading digital health care company with a mission to create trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.

We refer to certain financial measures that are not recognized under U.S. generally accepted accounting principles (GAAP) in this press release, including adjusted EBITDA, adjusted EBITDA margin, adjusted net income (loss), adjusted net income (loss) per diluted share, adjusted operating expenses and free cash flow. We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures may be helpful to investors. However, non-GAAP financial measures are presented for supplemental informational purposes only, have limitations as analytical tools, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our disclosure of non-GAAP financial measures as a tool for comparison. See the schedules attached to this press release for additional information and reconciliations of such non-GAAP financial measures. We have not reconciled our adjusted EBITDA margin estimates for full year 2026 because certain items that impact these figures are uncertain or out of our control and cannot be reasonably predicted. Accordingly, a reconciliation of adjusted EBITDA margin estimates is not available without unreasonable effort.

Adjusted EBITDA is defined as net income (loss) before income tax provision, depreciation and amortization, interest expense, and interest income and as further adjusted for stock-based compensation expense, changes in fair value of strategic investments, impairment charges, business transformation costs, certain intellectual property litigation expenses, certain litigation settlements (net of expected insurance recoveries), costs related to the cybersecurity incident (net of expected insurance recoveries), and loss on extinguishment of debt. Business transformation costs include costs associated with professional services, employee termination and relocation, third-party merger and acquisition, integration, and other costs to augment and restructure the organization, inclusive of both outsourced and offshore resources.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future actions or operating or financial performance. In particular, these statements include statements regarding our financial guidance, volume growth and margin expansion, market opportunity, ability to penetrate the market, expansion into new health programs, international market expansion, anticipated productivity and quality improvements, anticipated demand for our products and services and our expectations for growth, and statements regarding the anticipated benefits of the VitalConnect acquisition, including our ability to broaden our capabilities, advance our multi-vitals strategy, expand our addressable market and serve more patients across the continuum of care, our ability to create durable, long-term value for patients, clinicians and stockholders; and the anticipated benefits of our revolving credit facility. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: intense competition in the markets we compete in; fluctuations in our operating results; our ability to successfully integrate any acquisitions or strategic investments; risks associated with managing our growth; future U.S. and global political, competitive, reimbursement and regulatory conditions, including changing trade and tariff policies; geopolitical conflicts and tensions; distribution and supply chain disruptions and cost increases; new product and service introductions and the market acceptance of those products and services; expected pricing environment; intellectual property rights; litigation; financial market conditions; the execution and effect of our business strategy; and future business decisions made by us and our competitors. Additional risks are described in the section entitled “Risk Factors” and elsewhere in our filings made with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q expected to be filed on or about November 5, 2026. These forward- looking statements speak only as of the date of this press release and should not be unduly relied upon. iRhythm undertakes no obligation to update them except as required by law.

1. Russo P, Strom J, Nathan R, Song Y, Shokoohi M, Passman R, Reynolds M, Mittal S. Clinical and economic outcomes in diagnostic-naïve Medicare fee-for-service beneficiaries managed with alert-based ambulatory cardiac monitors: The CAMELOT- ALERT study. American Heart Journal . 2026 Aug 28. doi: 10.1016/j.ahj.2026.10759

2. Mittal S, Reynolds MR, Hughes A, Buysman EK, Hendrickson EM, Boyle K, Wright B, Ashburner JM, Turakhia M, Passman RS. Comparative Clinical Outcomes Across Ambulatory Cardiac Monitoring Modalities. Clin Cardiology. 2026 Oct;49(10):e70500. doi:10.1002/clc.70500

3. Knight BP, Pinkerton R, Ellis J, Ashburner JM, Wazni OM, Passman RS, Turakhia MP, Mittal M. Real-world performance and diagnostic yield gains of a next- generation patch-based 14-day uninterrupted ambulatory electrocardiogram monitor. Heart Rhythm O2. October 9, 2026. https://www.heartrhythmopen.com/article/S2666-5018(26)00597-0/fulltext

September 30, (unaudited) 2026 December 31, 2025 ────────────────────────────────────────────────────────────────────────────── Assets Current assets: Cash and cash $ 394,718 $ 236,012 equivalents Restricted cash 10,000 — Marketable 166,001 347,751 securities Accounts 81,126 75,706 receivable, net Inventory 23,222 21,634 Prepaid expenses and other current 55,143 21,662 assets Total current 730,210 702,765 assets Property and 176,938 151,599 equipment, net Operating lease right-of-use 37,670 41,827 assets Restricted cash 8,358 8,358 Goodwill 862 862 Long-term strategic 74,514 69,913 investments Other assets 62,889 44,718 Total assets $ 1,091,441 $ 1,020,042 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 15,395 $ 2,256 Accrued 167,630 128,747 liabilities Deferred revenue 4,668 4,201 Operating lease liabilities, 17,039 16,686 current portion Total current 204,732 151,890 liabilities Long-term senior 651,858 649,504 convertible notes Other noncurrent 908 908 liabilities Operating lease liabilities, 56,837 64,994 noncurrent portion Total liabilities 914,335 867,296 Stockholders’ equity: Preferred stock, $0.001 par value – 5,000 shares authorized; none — — issued and outstanding at September 30, 2026 and December 31, 2025 Common stock, $0.001 par value – 100,000 shares authorized; 33,414 shares issued and 33,185 shares 33 32 outstanding at September 30, 2026, and 32,526 shares issued and 32,297 shares outstanding at December 31, 2025 Additional 1,049,900 980,757 paid-in capital Accumulated other comprehensive -216 403 (loss) income Accumulated -847,611 -803,446 deficit Treasury stock, at cost; 229 shares at -25,000 -25,000 September 30, 2026 and December 31, 2025 Total stockholders’ 177,106 152,746 equity Total liabilities and stockholders’ $ 1,091,441 $ 1,020,042 equity

1 Net loss for the three and nine months ended September 30, 2026 includes $0.3 million and $0.9 million of acquired in-process research and development expense, and $0.3 million and $2.3 million for the three and nine months ended September 30, 2025, respectively.

2 Business transformation costs include $6.0 million associated with the VitalConnect acquisition for the three and nine months ended September 30, 2026.

3 Excludes third-party attorneys' fees and expenses associated with patent litigation brought against the Company by Welch Allyn, Inc. and Bardy Diagnostics, Inc., subsidiaries of Baxter International, Inc.

4 Excludes charges for Baxter patent litigation and securities class action litigation settlement, net of expected insurance recoveries.

5 Represents expenses directly related to the Cybersecurity Incident, net of expected insurance recoveries, including investigation and remediation, customer notifications, and professional and consultancy expenses.

7 The adjustments are for the transition from net loss per diluted share, as reported, to adjusted net income per diluted share, due to our dilutive securities, which include equity incentive awards and senior convertible notes.

8 Net cash provided by operating activities for the three and nine months ended September 30, 2026 includes $50.0 million of Baxter patent litigation settlement costs.

Full text with the tables
                                                                                
  Exhibit 99.1                                                                  
                                                                                
        iRhythm Holdings Announces Third Quarter 2026 Financial Results         
                                                                                
  SAN FRANCISCO, November 5, 2026                                               
                                                                                
-- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company
with a mission to create trusted solutions that detect, predict, and prevent
disease, today reported financial results for the three months ended September
30, 2026.
                                                                                
  Third Quarter 2026 Financial Highlights                                       
                                                                                
• Revenue of $221.6 million, a 14.9% increase compared to third quarter 2025

• Gross margin of 74.2%, a 310-basis point increase compared to third quarter
2025

• GAAP net loss of $29.9 million, a $24.6 million increase in net loss compared
to third quarter 2025

• Adjusted EBITDA and adjusted EBITDA margin of $51.2 million and 23.1%,
respectively, a $29.6 million and 1,190 - basis point improvement, respectively,
compared to third quarter 2025

• Unrestricted cash, cash equivalents, and marketable securities of $560.7
million as of September 30, 2026

• Increased fiscal year 2026 revenue guidance to $890 million to $895 million
and adjusted EBITDA margin guidance to 15.5% to 16.0%
                                                                                
  Recent Operational Highlights                                                 
                                                                                
• Delivered another strong quarter, driven by healthy volume-led revenue growth
of Zio Monitor and robust margin expansion, with broad-based momentum across
cardiology, primary care, innovative channels and international markets

• Completed the acquisition of VitalConnect on October 5, 2026, broadening our
cardiac monitoring portfolio with an immediate FDA-cleared mobile cardiac
telemetry offering, advancing our multi-vitals strategy, and expanding our
addressable market across the continuum of care

• Published three large-scale real world studies demonstrating product
superiority of Zio AT (CAMELOT-ALERT 1 ), Zio Long-Term Continuous Monitoring
(EXCALIBUR 2 ), and improvements in Zio Monitor performance and diagnostic yield
compared with Zio XT 3 in over 1.7 million total patients

• Submitted FDA 510(k) applications for pediatric use with our Zio Monitor long-
term continuous monitoring business

• Closed a new $300 million senior secured revolving credit facility on November
3, 2026, providing additional liquidity to support our long-term growth
objectives

“Our third quarter results reflect the continued strength of our core business.
Demand for Zio Monitor remains robust, exceeding our expectations in the
quarter, driven by volume growth across care settings and channels. We also
continued to take meaningful steps forward with significant margin expansion,
and consistent execution against our strategic priorities,” said Quentin
Blackford, President and Chief Executive Officer of iRhythm. “With the
acquisition of VitalConnect now closed, we are encouraged by the early
opportunities we see to broaden our capabilities and serve more patients within
the ambulatory cardiac monitoring market and across the continuum of care. With
an immediate FDA-cleared mobile cardiac telemetry device, we are excited to be
able to offer the marketplace a best-in-class MCT portfolio of options. We
remain focused on advancing innovation, expanding access to Zio, and investing
in the growth initiatives that we believe will create durable value for
patients, clinicians, and stockholders.”
                                                                                
  Third Quarter 2026 Financial Results                                          
                                                                                
Revenue for the third quarter of 2026 was $221.6 million, up 14.9% from $192.9
million during the same period in 2025. The increase was driven primarily by
sustained volume demand across our customer base, reflecting continued strength
in our core business and contributions from newer growth channels.

Gross profit for the third quarter of 2026 was $164.5 million, up 20.0% from
$137.1 million during the same period in 2025, while gross margin was 74.2%, a
310-basis point improvement compared to the third quarter of 2025. The increase
in gross profit was primarily due to increased volume of Zio services, as well
as a one-time benefit from tariff refunds of approximately $3.1 million. The
increase in gross margin was primarily driven by continued operational
efficiencies, product mix, a tariff refund one-time benefit, and disciplined
execution.
                                                                                
  Exhibit 99.1                                                                  
                                                                                
Operating expenses for the third quarter of 2026 were $197.0 million, compared
to $145.6 million for the same period in 2025. Adjusted operating expenses for
the third quarter of 2026 were $138.6 million, compared to $141.4 million during
the same period in 2025. The decrease in adjusted operating expenses, period
over period, reflects a disciplined approach to investment, as we funded key
growth initiatives while thoughtfully managing costs across the broader
organization.

GAAP net loss for the third quarter of 2026 was $29.9 million, or net loss per
diluted share of $0.90, compared with GAAP net loss of $5.2 million, or net loss
per diluted share of $0.16, for the same period in 2025. Adjusted net income for
the third quarter of 2026 was $27.8 million, or net income per diluted share of
$0.82, compared with an adjusted net loss of $2.0 million, or net loss per
diluted share of $0.06, for the same period in 2025. The improvement was
primarily driven by our revenue growth and operating leverage achieved through
implementation of efficiency initiatives.

Unrestricted cash, cash equivalents, and marketable securities were $560.7
million as of September 30, 2026.
                                                                                
  2026 Annual Guidance                                                          
                                                                                
For the full year 2026, iRhythm expects revenue between $890 million and $895
million, which includes approximately $16 million of expected VitalConnect
revenue contribution from the October 5, 2026 acquisition close through year-
end. iRhythm also expects adjusted EBITDA margin between 15.5% and 16.0%,
inclusive of VitalConnect. iRhythm’s guidance reflects continued volume-led
growth and operating leverage while maintaining disciplined investment in
innovation and market expansion.
                                                                                
  Webcast and Conference Call Information                                       
                                                                                
iRhythm’s management team will host a conference call today beginning at 1:30
p.m. PT/4:30 p.m. ET. Interested parties may access a live and archived webcast
of the presentation on the “Events & Presentations” section of the company’s
investor website at investors.irhythmtech.com.
                                                                                
  About iRhythm Holdings, Inc.                                                  
                                                                                
iRhythm is a leading digital health care company with a mission to create
trusted solutions that detect, predict, and prevent disease. Combining wearable
biosensors and cloud-based data analytics with powerful proprietary algorithms,
iRhythm distills data from millions of heartbeats into clinically actionable
information. Through a relentless focus on patient care, iRhythm’s vision is to
deliver better data, better insights, and better health for all.
                                                                                
  Use of Non-GAAP Financial Measures                                            
                                                                                
We refer to certain financial measures that are not recognized under U.S.
generally accepted accounting principles (GAAP) in this press release, including
adjusted EBITDA, adjusted EBITDA margin, adjusted net income (loss), adjusted
net income (loss) per diluted share, adjusted operating expenses and free cash
flow. We use these non-GAAP financial measures for financial and operational
decision-making and as a means to evaluate period-to-period comparisons. We
believe that these non-GAAP financial measures may be helpful to investors.
However, non-GAAP financial measures are presented for supplemental
informational purposes only, have limitations as analytical tools, and should
not be considered in isolation or as a substitute for financial information
presented in accordance with GAAP. In addition, other companies, including
companies in our industry, may calculate non-GAAP financial measures differently
or may use other measures to evaluate their performance, all of which could
reduce the usefulness of our disclosure of non-GAAP financial measures as a tool
for comparison. See the schedules attached to this press release for additional
information and reconciliations of such non-GAAP financial measures. We have not
reconciled our adjusted EBITDA margin estimates for full year 2026 because
certain items that impact these figures are uncertain or out of our control and
cannot be reasonably predicted. Accordingly, a reconciliation of adjusted EBITDA
margin estimates is not available without unreasonable effort.

Adjusted EBITDA is defined as net income (loss) before income tax provision,
depreciation and amortization, interest expense, and interest income and as
further adjusted for stock-based compensation expense, changes in fair value of
strategic investments, impairment charges, business transformation costs,
certain intellectual property litigation expenses, certain litigation
settlements (net of expected insurance recoveries), costs related to the
cybersecurity incident (net of expected insurance recoveries), and loss on
extinguishment of debt. Business transformation costs include costs associated
with professional services, employee termination and relocation, third-party
merger and acquisition, integration, and other costs to augment and restructure
the organization, inclusive of both outsourced and offshore resources.
                                                                                
  Exhibit 99.1                                                                  
                                                                                
                                                                                
  Forward-Looking Statements                                                    
                                                                                
This press release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995. An investor can identify these statements by the
fact that they do not relate strictly to historical or current facts. They use
words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’,
‘plan’, ‘believe’, ‘target’ and other words and terms of similar meaning in
connection with any discussion of future actions or operating or financial
performance. In particular, these statements include statements regarding our
financial guidance, volume growth and margin expansion, market opportunity,
ability to penetrate the market, expansion into new health programs,
international market expansion, anticipated productivity and quality
improvements, anticipated demand for our products and services and our
expectations for growth, and statements regarding the anticipated benefits of
the VitalConnect acquisition, including our ability to broaden our capabilities,
advance our multi-vitals strategy, expand our addressable market and serve more
patients across the continuum of care, our ability to create durable, long-term
value for patients, clinicians and stockholders; and the anticipated benefits of
our revolving credit facility. Such statements are based on current assumptions
that involve risks and uncertainties that could cause actual outcomes and
results to differ materially. These risks and uncertainties, many of which are
beyond our control, include, but are not limited to: intense competition in the
markets we compete in; fluctuations in our operating results; our ability to
successfully integrate any acquisitions or strategic investments; risks
associated with managing our growth; future U.S. and global political,
competitive, reimbursement and regulatory conditions, including changing trade
and tariff policies; geopolitical conflicts and tensions; distribution and
supply chain disruptions and cost increases; new product and service
introductions and the market acceptance of those products and services; expected
pricing environment; intellectual property rights; litigation; financial market
conditions; the execution and effect of our business strategy; and future
business decisions made by us and our competitors. Additional risks are
described in the section entitled “Risk Factors” and elsewhere in our filings
made with the Securities and Exchange Commission, including our Quarterly Report
on Form 10-Q expected to be filed on or about November 5, 2026. These forward-
looking statements speak only as of the date of this press release and should
not be unduly relied upon. iRhythm undertakes no obligation to update them
except as required by law.
                                                                                
  Investor Contact                                                              
                                                                                
Francis Pruell

[email protected]
                                                                                
  Media Contact                                                                 
                                                                                
Kassandra Perry

[email protected]

1. Russo P, Strom J, Nathan R, Song Y, Shokoohi M, Passman R, Reynolds M, Mittal
S. Clinical and economic outcomes in diagnostic-naïve Medicare fee-for-service
beneficiaries managed with alert-based ambulatory cardiac monitors: The CAMELOT-
ALERT study. American Heart Journal . 2026 Aug 28. doi: 10.1016/j.ahj.2026.10759

2. Mittal S, Reynolds MR, Hughes A, Buysman EK, Hendrickson EM, Boyle K, Wright
B, Ashburner JM, Turakhia M, Passman RS. Comparative Clinical Outcomes Across
Ambulatory Cardiac Monitoring Modalities. Clin Cardiology. 2026
Oct;49(10):e70500. doi:10.1002/clc.70500

3. Knight BP, Pinkerton R, Ellis J, Ashburner JM, Wazni OM, Passman RS, Turakhia
MP, Mittal M. Real-world performance and diagnostic yield gains of a next-
generation patch-based 14-day uninterrupted ambulatory electrocardiogram
monitor. Heart Rhythm O2. October 9, 2026.
https://www.heartrhythmopen.com/article/S2666-5018(26)00597-0/fulltext
                                                                                
  Exhibit 99.1                                                                  
                                                                                
                                                                                
                             IRHYTHM HOLDINGS, INC.                             
                                                                                
                                                                                
                     Condensed Consolidated Balance Sheets                      
                                                                                
                        (in thousands, except par value)                        
                                                                                
                                         September 30,                          
                     (unaudited)                  2026       December 31, 2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Assets                                                                        
  Current assets:                                                               
  Cash and cash                   $            394,718    $            236,012  
  equivalents                                                                   
  Restricted cash                               10,000                       —  
  Marketable                                   166,001                 347,751  
  securities                                                                    
  Accounts                                      81,126                  75,706  
  receivable, net                                                               
  Inventory                                     23,222                  21,634  
  Prepaid expenses                                                              
  and other current                             55,143                  21,662  
  assets                                                                        
  Total current                                730,210                 702,765  
  assets                                                                        
  Property and                                 176,938                 151,599  
  equipment, net                                                                
  Operating lease                                                               
  right-of-use                                  37,670                  41,827  
  assets                                                                        
  Restricted cash                                8,358                   8,358  
  Goodwill                                         862                     862  
  Long-term                                                                     
  strategic                                     74,514                  69,913  
  investments                                                                   
  Other assets                                  62,889                  44,718  
  Total assets                    $          1,091,441    $          1,020,042  
  Liabilities and                                                               
  Stockholders’                                                                 
  Equity                                                                        
  Current                                                                       
  liabilities:                                                                  
  Accounts payable                $             15,395    $              2,256  
  Accrued                                      167,630                 128,747  
  liabilities                                                                   
  Deferred revenue                               4,668                   4,201  
  Operating lease                                                               
  liabilities,                                  17,039                  16,686  
  current                                                                       
  portion                                                                       
  Total current                                204,732                 151,890  
  liabilities                                                                   
  Long-term senior                             651,858                 649,504  
  convertible notes                                                             
  Other noncurrent                                 908                     908  
  liabilities                                                                   
  Operating lease                                                               
  liabilities,                                  56,837                  64,994  
  noncurrent                                                                    
  portion                                                                       
  Total liabilities                            914,335                 867,296  
  Stockholders’                                                                 
  equity:                                                                       
  Preferred stock,                                                              
  $0.001 par value                                                              
  –                                                                             
  5,000 shares                                                                  
  authorized; none                                   —                       —  
  issued and                                                                    
  outstanding at                                                                
  September 30,                                                                 
  2026 and                                                                      
  December 31, 2025                                                             
  Common stock,                                                                 
  $0.001 par value                                                              
  – 100,000                                                                     
  shares                                                                        
  authorized;                                                                   
  33,414 shares                                                                 
  issued                                                                        
  and 33,185 shares                                 33                      32  
  outstanding at                                                                
  September 30,                                                                 
  2026, and 32,526                                                              
  shares                                                                        
  issued and 32,297                                                             
  shares                                                                        
  outstanding at                                                                
  December 31, 2025                                                             
  Additional                                 1,049,900                 980,757  
  paid-in capital                                                               
  Accumulated other                                                             
  comprehensive                                   -216                     403  
  (loss)                                                                        
  income                                                                        
  Accumulated                                 -847,611                -803,446  
  deficit                                                                       
  Treasury stock,                                                               
  at cost; 229                                                                  
  shares at                                    -25,000                 -25,000  
  September 30,                                                                 
  2026 and December                                                             
  31, 2025                                                                      
  Total                                                                         
  stockholders’                                177,106                 152,746  
  equity                                                                        
  Total liabilities                                                             
  and stockholders’               $          1,091,441    $          1,020,042  
  equity                                                                        
                                                                                
                                                                                
  Exhibit 99.1                                                                  
                                                                                
                                                                                
                             IRHYTHM HOLDINGS, INC.                             
                                                                                
                                                                                
                Condensed Consolidated Statements of Operations                 
                                                                                
                     (in thousands, except per share data)                      
                                                                                
                     Three                               Nine                   
                    Months                             Months                   
                     Ended                              Ended                   
                   Septem…                           Septemb…                   
  (unaud…    2026      30,    2025             2026       30,    2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Revenu…    $     221,592    $     192,884    $      645,154    $     538,248  
  net                                                                           
  Cost of           57,098           55,762           176,102          159,053  
  revenue                                                                       
  Gross            164,494          137,122           469,052          379,195  
  profit                                                                        
  Operat…                                                                       
  expens…                                                                       
  Resear…                                                                       
  and               20,599           21,033            61,800           63,564  
  develo…                                                                       
  Acquir…                                                                       
  in-pro…                                                                       
  resear…              303              302               898            2,296  
  and                                                                           
  develo…                                                                       
  Sellin…                                                                       
  general          125,636          124,216           393,175          370,549  
  and                                                                           
  admini…                                                                       
  Litiga…           49,788                —            63,738                —  
  settle…                                                                       
  Impair…              723                —               723            2,479  
  charges                                                                       
  Total                                                                         
  operat…          197,049          145,551           520,334          438,888  
  expens…                                                                       
  Loss                                                                          
  from             -32,555           -8,429           -51,282          -59,693  
  operat…                                                                       
  Intere…                                                                       
  and                                                                           
  other                                                                         
  income,                                                                       
  net:                                                                          
  Intere…            4,699            5,944            14,354           16,184  
  income                                                                        
  Intere…           -3,298           -3,281            -9,882           -9,832  
  expense                                                                       
  Other                                                                         
  income,            1,303              578             3,145            3,717  
  net                                                                           
  Total                                                                         
  intere…                                                                       
  and                2,704            3,241             7,617           10,069  
  other                                                                         
  income,                                                                       
  net                                                                           
  Loss                                                                          
  before           -29,851           -5,188           -43,665          -49,624  
  income                                                                        
  taxes                                                                         
  Income                                                                        
  tax                    —               24               500              506  
  provis…                                                                       
  Net        $     -29,851    $      -5,212    $      -44,165    $     -50,130  
  loss                                                                          
  Net                                                                           
  loss                                                                          
  per                                                                           
  common     $       -0.90    $       -0.16    $        -1.35    $       -1.57  
  share,                                                                        
  basic                                                                         
  and                                                                           
  diluted                                                                       
  Weight…                                                                       
  shares,                                                                       
  basic             33,099           32,170            32,836           31,919  
  and                                                                           
  diluted                                                                       
                                                                                
                                                                                
  Exhibit 99.1                                                                  
                                                                                
                                                                                
                             IRHYTHM HOLDINGS, INC.                             
                                                                                
                                                                                
            Reconciliation of GAAP to Non-GAAP Financial Information            
                                                                                
                     (in thousands, except per share data)                      
                                                                                
            Three                              Nine                             
            Months                             Months                           
  (unau…    Ended                              Ended                            
  Adjus…    Septe…                             Septe…                           
  EBITDA    30,                                30,                              
  recon…    2026               2025            2026               2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  loss,     $       -29,851    $     -5,212    $       -44,165    $     -50,1…  
  as                                                                            
  repor…                                                                        
  Inter…              3,298           3,281              9,882           9,832  
  expen…                                                                        
  Inter…             -4,699          -5,944            -14,354          -16,1…  
  income                                                                        
  Chang…                                                                        
  in                                                                            
  fair                                                                          
  value                -832            -894             -3,101          -3,889  
  of                                                                            
  strat…                                                                        
  inves…                                                                        
  Income                                                                        
  tax                     —              24                500             506  
  provi…                                                                        
  Depre…                                                                        
  and                 5,324           5,173             15,588          15,488  
  amort…                                                                        
  Stock…             19,490          21,006             61,020          67,177  
  compe…                                                                        
  Impai…                723               —                723           2,479  
  charg…                                                                        
  Busin…                                                                        
  trans…              6,590             913              8,094           2,341  
  costs2                                                                        
  Intel…                                                                        
  prope…              1,211           3,212              9,828           7,000  
  litig…                                                                        
  expen…                                                                        
  Litig…             49,788               —             63,738               —  
  settl…                                                                        
  Cyber…                142               —                828               —  
  incid…                                                                        
  Adjus…    $        51,184    $     21,559    $       108,581    $     34,620  
  EBITDA                                                                        
  Adjus…                                                                        
  net                                                                           
  income                                                                        
  (loss)                                                                        
  recon…                                                                        
  Net                                                                           
  loss,     $       -29,851    $     -5,212    $       -44,165    $     -50,1…  
  as                                                                            
  repor…                                                                        
  Impai…                723               —                723           2,479  
  charg…                                                                        
  Busin…                                                                        
  trans…              6,590             913              8,094           2,341  
  costs2                                                                        
  Intel…                                                                        
  prope…              1,211           3,212              9,828           7,000  
  litig…                                                                        
  expen…                                                                        
  Chang…                                                                        
  in                                                                            
  fair                                                                          
  value                -832            -894             -3,101          -3,889  
  of                                                                            
  strat…                                                                        
  inves…                                                                        
  Litig…             49,788               —             63,738               —  
  settl…                                                                        
  Cyber…                142               —                828               —  
  incid…                                                                        
  Tax                                                                           
  effect                 44               5               -153            -300  
  of                                                                            
  adjus…                                                                        
  Adjus…                                                                        
  net       $        27,815    $     -1,976    $        35,792    $     -42,4…  
  income                                                                        
  (loss)                                                                        
  Inter…                                                                        
  expen…                                                                        
  on                                                                            
  senior    $         3,298    $          —    $             —    $          —  
  conve…                                                                        
  notes,                                                                        
  net of                                                                        
  tax                                                                           
  Numer…                                                                        
  used                                                                          
  in                                                                            
  compu…                                                                        
  adjus…                                                                        
  net       $        31,113    $     -1,976    $        35,792    $     -42,4…  
  income                                                                        
  (loss)                                                                        
  per                                                                           
  dilut…                                                                        
  share                                                                         
                                                                                
                                                                                
  Exhibit 99.1                                                                  
                                                                                
                                                                                
                             IRHYTHM HOLDINGS, INC.                             
                                                                                
      Reconciliation of GAAP to Non-GAAP Financial Information (continued)      
                                                                                
                     (in thousands, except per share data)                      
                                                                                
  (una…                                                                         
  Adju…                                                                         
  net                                                                           
  inco…    Three                               Nine                             
  (los…    Months                              Months                           
  per      Ended                               Ended                            
  dilu…    Septem…                             Septe…                           
  share    30,                                 30,                              
  reco…    2026               2025             2026               2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  loss,    $         -0.90    $       -0.16    $         -1.35    $      -1.57  
  as                                                                            
  repo…                                                                         
  Impa…               0.02                —               0.02            0.08  
  char…                                                                         
  Busi…                                                                         
  tran…               0.17             0.03               0.24            0.07  
  cost…                                                                         
  Inte…                                                                         
  prop…               0.03             0.10               0.29            0.22  
  liti…                                                                         
  expe…                                                                         
  Chan…                                                                         
  in                                                                            
  fair                                                                          
  value              -0.02            -0.03              -0.09           -0.12  
  of                                                                            
  stra…                                                                         
  inve…                                                                         
  Liti…               1.31                —               1.90               —  
  sett…                                                                         
  Cybe…                  —                —               0.02               —  
  inci…                                                                         
  Tax                                                                           
  effe…                  —                —                  —           -0.01  
  of                                                                            
  adju…                                                                         
  Inte…                                                                         
  expe…                                                                         
  on                                                                            
  seni…                                                                         
  conv…               0.09                —                  —               —  
  note…                                                                         
  net                                                                           
  of                                                                            
  tax                                                                           
  Impa…                                                                         
  of                                                                            
  adju…                                                                         
  to                  0.12                —               0.04               —  
  dilu…                                                                         
  shar…                                                                         
  as                                                                            
  repo…                                                                         
  Adju…                                                                         
  net                                                                           
  inco…                                                                         
  (los…    $          0.82    $       -0.06    $          1.07    $      -1.33  
  per                                                                           
  dilu…                                                                         
  share                                                                         
  Weig…                                                                         
  shar…                                                                         
  basic                                                                         
  and               33,099           32,170             32,836          31,919  
  dilu…                                                                         
  as                                                                            
  repo…                                                                         
  Equi…                                                                         
  ince…                337                —                634               —  
  awar…                                                                         
  Seni…                                                                         
  conv…              4,492                —                  —               —  
  notes                                                                         
  Weig…                                                                         
  shar…                                                                         
  used                                                                          
  in                                                                            
  comp…                                                                         
  adju…             37,928           32,170             33,470          31,919  
  net                                                                           
  inco…                                                                         
  (los…                                                                         
  per                                                                           
  dilu…                                                                         
  share                                                                         
  Adju…                                                                         
  oper…                                                                         
  expe…                                                                         
  reco…                                                                         
  Oper…                                                                         
  expe…    $        197,0…    $     145,551    $       520,334    $     438,8…  
  as                                                                            
  repo…                                                                         
  Impa…               -723                —               -723          -2,479  
  char…                                                                         
  Busi…                                                                         
  tran…             -6,590             -913             -8,094          -2,341  
  cost…                                                                         
  Inte…                                                                         
  prop…             -1,211           -3,212             -9,828          -7,000  
  liti…                                                                         
  expe…                                                                         
  Liti…             -49,7…                —            -63,738               —  
  sett…                                                                         
  Cybe…               -142                —               -828               —  
  inci…                                                                         
  Adju…                                                                         
  oper…    $        138,5…    $     141,426    $       437,123    $     427,0…  
  expe…                                                                         
  Free                                                                          
  cash                                                                          
  flow                                                                          
  reco…                                                                         
  Net                                                                           
  cash                                                                          
  prov…    $         4,438    $      34,883    $        29,345    $     54,651  
  by                                                                            
  oper…                                                                         
  acti…                                                                         
  Less:                                                                         
  Purc…                                                                         
  of                -15,9…          -14,831            -36,453          -34,6…  
  prop…                                                                         
  and                                                                           
  equi…                                                                         
  Free                                                                          
  cash     $        -11,5…    $      20,052    $        -7,108    $     20,032  
  flow                                                                          
                                                                                
*Certain numbers expressed may not sum due to rounding.

1 Net loss for the three and nine months ended September 30, 2026 includes $0.3
million and $0.9 million of acquired in-process research and development
expense, and $0.3 million and $2.3 million for the three and nine months ended
September 30, 2025, respectively.

2 Business transformation costs include $6.0 million associated with the
VitalConnect acquisition for the three and nine months ended September 30, 2026.

3 Excludes third-party attorneys' fees and expenses associated with patent
litigation brought against the Company by Welch Allyn, Inc. and Bardy
Diagnostics, Inc., subsidiaries of Baxter International, Inc.

4 Excludes charges for Baxter patent litigation and securities class action
litigation settlement, net of expected insurance recoveries.

5 Represents expenses directly related to the Cybersecurity Incident, net of
expected insurance recoveries, including investigation and remediation, customer
notifications, and professional and consultancy expenses.

6 Income tax impact of Non-GAAP adjustments listed.

7 The adjustments are for the transition from net loss per diluted share, as
reported, to adjusted net income per diluted share, due to our dilutive
securities, which include equity incentive awards and senior convertible notes.

8 Net cash provided by operating activities for the three and nine months ended
September 30, 2026 includes $50.0 million of Baxter patent litigation settlement
costs.

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/IRTC/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.